AB 2000 inserts a short statement of legislative intent guarding against mid‑year health plan formulary changes that disrupt patient care and makes targeted, non‑substantive edits to Section 1367.22 of the Health and Safety Code. The statutory text retains the existing rule that a health care service plan cannot drop coverage for a drug an enrollee was already receiving where the prescribing provider continues that prescription and the drug is appropriate, while streamlining language and clarifying who counts as a prescribing provider.
The bill also restates existing limitations: it excludes drugs prescribed for uses different from the FDA‑approved marketing use, preserves other continuity‑of‑care obligations in the chapter, and keeps the plan’s ability to impose copayments, deductibles, or maximum coverage limits so long as those cost terms are reported to—and not objected to by—the director. For compliance teams and plan counsel, AB 2000 mainly removes drafting clutter and nudges attention back to how formulary change procedures, disclosures, and DMHC review interact with patient continuity of care.
At a Glance
What It Does
Declares legislative intent to protect patients from mid‑year formulary changes and revises Section 1367.22’s wording to clarify continuity‑of‑care protections for enrollees already receiving a drug. It explicitly includes providers authorized under Business and Professions Code Section 4059(a) in the definition of prescribing providers.
Who It Affects
Health care service plans licensed under Knox‑Keene, prescribing clinicians (including those covered by B&P 4059(a)), pharmacies, plan compliance personnel, and the Department of Managed Health Care (DMHC), which reviews plan disclosures.
Why It Matters
The bill reduces textual ambiguity around who can preserve access to a previously covered drug, preserves DMHC’s disclosure role, and signals legislative concern about formulary disruptions—issues that affect formulary change processes, prior authorization workflows, and regulator oversight.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 2000 does two things: it adds a legislative intent statement and it cleans up Section 1367.22’s language without introducing new substantive obligations. The intent clause declares that the Legislature aims to protect patients from mid‑year formulary changes that would interrupt care or restrict access to medically necessary medications.
That sentence itself does not amend coverage rules but signals legislative priorities for regulators and courts to consider when interpreting the statute.
The statutory edits tidy up subsection (a) of Section 1367.22 but leave its core rule intact: when a health plan has previously approved coverage for a drug to treat an enrollee’s condition and the plan’s prescribing provider continues to prescribe the same drug appropriately, the plan may not limit or exclude coverage for that drug. The bill clarifies that a prescribing provider includes providers authorized to write prescriptions under Business and Professions Code Section 4059(a), which brings the definition in closer alignment with existing professional licensure categories.AB 2000 keeps the preexisting carve‑outs and cross‑references: drugs prescribed for uses other than the FDA‑approved marketed use remain governed by Section 1367.21, the broader chapter’s continuity‑of‑care obligations remain in force, and plans continue to be permitted to collect copayments, deductibles, or set maximum coverage limits for prescription benefits—provided those financial terms are reported to the DMHC director and not objected to.
Practically, the bill asks plans to ensure their disclosure materials and formulary change procedures reflect these clarified drafting points and reinforces that DMHC review of plan disclosures is a relevant compliance step.
The Five Things You Need to Know
AB 2000 adds an explicit legislative intent that aims to protect patients from mid‑year formulary changes that disrupt continuity of care.
The bill revises Health & Safety Code Section 1367.22 but leaves the substantive prohibition intact: plans may not stop covering a drug previously approved for an enrollee when the prescribing provider continues to prescribe it appropriately.
AB 2000 expressly defines a 'prescribing provider' to include providers authorized to write prescriptions under Business and Professions Code Section 4059(a).
Drugs prescribed for uses different from the FDA‑approved marketed use remain excluded from this subsection and are subject to Section 1367.21.
Plans may continue charging copayments, deductibles, or setting maximum prescription coverage limits so long as those terms are reported to the DMHC director and 'held unobjectionable' by the director.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative intent on mid‑year formulary changes
This single new sentence states the Legislature’s intent to shield patients from mid‑year formulary changes that disrupt care. It does not create a new private right or a new regulatory enforcement mechanism; its legal effect is interpretive — a tool for courts and regulators to weigh when construing statutory provisions or adjudicating disputes about formulary changes.
Continuity‑of‑coverage for previously approved drugs
Subsection (a) retains the substantive rule that a plan cannot limit coverage for a drug that the plan previously approved for an enrollee when the prescribing provider continues that prescription and the drug remains appropriate and safe. The amendment streamlines wording and explicitly imports the prescribing‑provider definition from Business and Professions Code Section 4059(a), clarifying which clinician categories can preserve access under this provision.
Exclusion for off‑label/different‑use prescriptions
Subsection (b) reaffirms that the continuity rule does not apply to prescriptions written for uses different from the drug’s FDA‑approved marketed use; those cases fall under Section 1367.21. Practically, this preserves existing prior‑authorization and medical‑necessity review pathways for off‑label prescribing.
No impairment of other chapter obligations
Subsection (c) confirms the amendment does not alter or limit other obligations in the Knox‑Keene chapter—most notably the broader continuity‑of‑care duty in Section 1367 and the requirement that medical decisions be rendered by qualified providers. This keeps the continuity standard situated within the chapter’s overall patient‑care framework.
Cost‑sharing and DMHC disclosure role
Subsection (d) preserves plans’ authority to impose copayments, deductibles, or maximum coverage limits for drugs, but conditions that authority on reporting those terms to the DMHC director and having them 'held unobjectionable.' That phrase imports a DMHC oversight role for plan disclosures and places a procedural checkpoint between plan cost‑sharing design and enrollee disclosure.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Enrollees on stable, ongoing drug regimens — The bill reinforces that previously covered medications should remain available when continued by a prescribing provider, reducing the risk of mid‑treatment disruptions.
- Prescribing clinicians — By clarifying that providers authorized under B&P Section 4059(a) count as prescribing providers, clinicians who manage chronic medications have firmer footing to request continued coverage for their patients.
- Patient‑advocacy organizations — The legislative intent statement gives advocates an interpretive lever when pushing regulators or plans to limit disruptive formulary changes.
Who Bears the Cost
- Health care service plans — Plans must ensure formularies, contract language, and disclosure procedures align with the clarified statutory text and may face more scrutiny from DMHC on mid‑year changes and disclosures.
- Plan compliance and legal teams — Updating consumer disclosures, internal policies, and training to reflect the clarified provider definition and DMHC reporting expectations will require administrative work.
- DMHC — The director’s role in holding cost‑sharing terms 'unobjectionable' may increase review workload and require clearer internal standards and processes for evaluating plan disclosures.
Key Issues
The Core Tension
The bill embodies the classic trade‑off between protecting individual continuity of care and preserving a plan’s ability to manage formularies and control costs: it signals that continuity matters without stripping plans of formulary tools, but it stops short of defining clear regulatory processes or standards for DMHC review, leaving regulators and plans to balance those competing aims in practice.
AB 2000 largely trims and clarifies existing statutory language rather than creating new substantive rights or remedies. That makes the bill low on novel policy content but high on interpretive importance: the added intent language signals legislative concern about formulary stability, which could influence how DMHC or courts resolve disputes over mid‑year changes.
However, because the intent statement carries no enforcement mechanism, its practical effect depends on how regulators and adjudicators choose to treat it.
Several implementation questions remain. The bill tightens the definition of a prescribing provider by referencing Business and Professions Code Section 4059(a), but practitioners and plans may disagree over whether particular advanced practice clinicians or physician assistants are covered in specific scenarios without additional regulatory guidance.
The requirement that copayments, deductibles, or coverage limits be 'reported to, and held unobjectionable by, the director' leaves open what standards, timelines, or procedures DMHC will use to review and object. Finally, the statute continues to carve out drugs prescribed for uses different than the FDA‑approved marketing use, leaving open interaction points with prior authorization, step therapy, and utilization management tools that plans employ to control costs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.